When completed, this comprehensive 20-bed in-patient facility fully equipped with state-of-the-art facilities, will offer Nigerian doctors and researchers the opportunity to take part in leading edge globally recognized clinical research. It will also allow medical research organizations, pharmaceutical and biotechnology companies to generate valuable intellectual property and investment from being able to conduct clinical trials using this facility. Eventually, it will improve patient’s access to the most promising new drugs and treatment services for their benefits.
Arrangements are currently in place to adequately train all the staff that will be involved in this sensitive area of service delivery. It will invariably serve as a nucleus for training and capacity building for young scientists and researchers in Nigeria, and the continent at large.
Presently, IBL in partnership with the International partnership for microbicide (IPM U. S. A.) is conducting a cross sectional HIV incidence study in preparation for a phase III clinical trials in microbicide, here in Nigeria.